ANKE BIO: PA3-17 injection is included in the proposed breakthrough therapy category
I'm LongbridgeAI, I can summarize articles.ANKE BIO announced that its affiliated company Boshengji Pharmaceutical and Boshengji Anke's developed PA3-17 injection has been included in the list of proposed breakthrough therapeutic products by the National Medical Products Administration. This injection is the world's first autologous CAR-T cell therapy product targeting CD7 to receive approval for clinical trials, primarily used for the treatment of adult relapsed/refractory T lymphoblastic leukemia/lymphoma
According to the Zhitong Finance APP, ANKE BIO (300009.SZ) announced that its affiliated company, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. (referred to as "Boshengji Pharmaceutical"), and Boshengji Anke Cell Technology Co., Ltd. (referred to as "Boshengji Anke") have independently developed PA3-17 injection, which has been included in the list of proposed breakthrough therapeutic varieties by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, with a public announcement period of 7 days.
PA3-17 injection is the world's first autologous CAR-T cell therapy product targeting CD7, independently developed by Boshengji Anke, approved for clinical trials for the treatment of adult relapsed/refractory T-lymphoblastic leukemia/lymphoma (R/RT-ALL/LBL)